RxDoctor Payments Data

Subha Clarke

Internal Medicine · Wilbraham, MANPI 1477572436

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,823 of the $2,501 with a category attached, or 72.9%. Eli Lilly accounts for 98.1% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $1,414 and has fallen 96.7% since, to $47 in 2022. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,501in general payments, 2019–2025

Across 49 payments — averaging $51.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$2K
  • Xeris Pharmaceuticals, Inc.$47
$1,286,572in research payments, 2019–2025

Across 155 payments — averaging $8300.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$457K
  • Eli Lilly$401K
  • Modernatx, Inc.$213K
  • Akebia Therapeutics Inc$73K
  • AbbVie$60K
  • Kowa Research Institute, Inc.$49K
  • plus $34K from 7 others

What the payments were for

  • Travel & lodging$1,82373%
  • Food & beverage$67827%

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly47$2,454
Xeris Pharmaceuticals, Inc.2$47

How this compares

$2,501 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts →

Other internal medicine in Wilbraham

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →